RESULTS: The median age at diagnosis was 73 (IQR 64, 80) with a median LRM size of 4.9cm (IQR 4.0, 6.7). Median follow up was 4 years (IQR 2.2, 7.3). Charlson comorbidity index was 2 in 59% of patients, and 32% had other non-renal malignancies. 19% of patients had or developed non-RCC metastasis from another malignancy. Median LRM growth rate was 0.4 cm/year (IQR 0.1, 0.8). We did not find a significant association between clinical factors and LRM growth. AS was discontinued in 34 patients who underwent surgical intervention after a median follow up of 1.9 years, 88% had malignant disease. Among 56 patients who underwent surgery or biopsy during AS, 82% had malignant histology. Median follow up for patients who did not undergo surgery was 3.3 years (IQR 1.9, 5.0). In total, 10 patients developed metastatic RCC (3 of whom died from RCC), and 29 patients died from other causes. Four treated patients progressed to RCC metastases, and 3 RCC-related mortality. Median follow up for metastasis free survivors was 4 years (IQR 2.2, 6.8). The 5-year probability of non-RCC related death and RCC metastasis was 26% and 7%, respectively. CONCLUSIONS: In highly comorbid patients, such as those with other advanced malignancies, active surveillance and expectant management of LRM has a low likelihood for RCC progression which is overshadowed by the risk of non-RCC related death. This data supports the use of surveillance of LRM as an acceptable strategy for selected patients with competing risks from other serious illnesses.
INTRODUCTION AND OBJECTIVES: The natural history of small renal masses (T1a) has been well defined leading to the recommendation of considering active surveillance as a viable option for the management of such masses in the elderly. Less clear, however, is the management of larger masses in such patients. The treatment of masses over 4 cm in the elderly and infirm is often contingent on a competing risk of death analysis with other comorbidities. The objective of this study is to define the natural history, including the growth rate and metastatic risk, of large and untreated renal masses in order to better council patients on their competing risks.
METHODS: A search was conducted into the imaging database at our centre for renal masses between 2005 and 2016. The search results were then reviewed by a radiologist. Renal masses concerning for renal cell carcinoma by imaging measuring over 4 cm and that had at least 2 cross-sectional imaging studies greater than 6 months apart were included. The 3 dimensional measurements of each renal mass were performed by one radiologist. A retrospective review of each patient's clinical chart was also conducted. Growth rates of the maximal tumor dimension were calculated. 95% confidence intervals using t-test were completed. Metastatic rates, cancer specific and overall mortality were also evaluated. RESULTS: We found 68 patients who met the inclusion criteria. Mean age at study entry was 75.5 years, mean eGFR was 57.5 ml/min/ 1.73m2. Mean tumor maximal dimension at study entry was 5.6cm and mean follow up was 2.5 years. 46 patients did no develop metastasis during the follow-up period and showed a growth rate of 0.67 cm/year (95% CI: 0.34 cm/yr to 1 cm/yr). 15 patients (22%) developed metastasis during follow-up with a mean tumor growth rate of 0.98 cm/year (95% CI: 0.33 cm/yr to 1.63 cm/yr). 7 patients had metastasis at presentation and were not treated and they showed a growth rate of 1.47 cm/year (95% CI: 0.37 cm/yr to 2.57 cm/yr). 10 patients progressed to radical nephrectomy; 2 progressed to partial nephrectomy. 17 (25%) patients died of metastatic RCC, 17 (25%) died of other causes. Overall and cancer specific survival were 50% and 75%, respectively. CONCLUSIONS: Large renal masses (> 4cm) have a higher growth rate than that reported for small renal masses. There is a tendency for the growth rate to increase in those who are likely to develop metastasis. Cancer specific survival in our cohort was 75% at a mean follow up of 2.5 years. Selection criteria for recommending observation of larger renal masses (>4cm) need to be more stringent than small renal masses reserving it only for much sicker and older patients.
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PREDICTING LOW METASTATIC POTENTIAL TUMORS USING CLINICAL RADIOGRAPHIC SIZE: A SYSTEMATIC REVIEW OF THE LITERATURE.
Alice Semerjian*, Hiten D. Patel, Michael A. Gorin, Michael H. Johnson, Mohamad Allaf, Phillip M. Pierorazio, Baltimore, MD INTRODUCTION AND OBJECTIVES: As detection of renal masses occurs earlier and at smaller sizes with widespread use of cross-sectional imaging, a significant portion of patients with small renal masses undergo intervention and are found to have benign or lowgrade pathology. There is an inverse relationship between the incidence of these masses that have low metastatic potential and size on preoperative imaging. The purpose of this study is to quantify proportion of low risk masses based on size, and quantify number of low risk masses being surgically removed METHODS: We systematically reviewed the literature for studies that included pathologic findings after surgical removal of renal masses. The studies must state tumor grade and number of benign masses removed stratified by radiographic size. Studies that did not include surgical pathology were excluded.
RESULTS: A total of 602 titles were reviewed for relevance. 144 abstracts were selected and reviewed according to inclusion criteria. Six full text articles that included tumor grade and benign versus malignant histology stratified by tumor size were included. Pooled estimates of low risk renal masses (benign and grade one) were 43.1%, 38.8%, 28.3%, 26.6%, and 15.7% for size groupings 0-2cm, 2-3cm, 3-4cm, 4-6cm and >6cm, respectively. If including grade 2 tumors, the percentages increase, leaving only 6.9%, 11.1%, 17%, 25%, and 33.5% high-grade (grade 3 or 4) tumors in respective size groupings (Figure 1) . CONCLUSIONS: The pooled estimates of patients with low grade or benign surgical pathology that had been resected clearly demonstrate a substantial portion of patients with small renal masses that have low metastatic potential are undergoing surgery for removal. As the diameter of a renal mass on preoperative cross sectional imaging decreases, the tumor grade and proportion of malignant pathology does as well. This information is essential to patient counseling and decision-making regarding placement on active surveillance. These findings could be especially helpful in the growing population of elderly patients with significant medical comorbidities. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1137
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